High flow nasal cannula oxygen therapy in acute respiratory failure from acute exacerbation of fibrotic interstitial lung disease
Autor: | Joares Luiz moretti, Fernanda Machado Balzan, Fernando Nataniel Vieira, Bruna Maciel Catarino, Eder Chaves Pacheco, Augusto Savi |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
interstitial lung disease
Exacerbation Respiratory rate business.industry medicine.medical_treatment Interstitial lung disease respiratory failure high flow nasal cannula General Medicine Emergency department respiratory system medicine.disease_cause medicine.disease respiratory tract diseases Respiratory failure Oxygen therapy Anesthesia medicine Medicine business High flow Nasal cannula respiratory falilure |
Zdroj: | Clinical and Biomedical Research, Vol 40, Iss 1 (2020) Clinical & Biomedical Research; Vol. 40 No. 1 (2020) Clinical and Biomedical Research; v. 40 n. 1 (2020) Clinical and Biomedical Research Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
ISSN: | 2357-9730 |
Popis: | Introduction. High flow nasal cannula oxygen therapy (HFNC) has become frequent in the treatment of patients with acute hypoxemic respiratory failure. Methods. Eleven patients with acute exacerbation of fibrotic interstitial lung disease (ILD) were treated with HFNC after failure of conventional therapy (SatO 2 < 90% offering 100% FiO 2 by non-rebreathing mask or noninvasive ventilation). Results. Ten patients had success with HFNC (not requiring orotracheal intubation) during emergency department admission. HFNC significantly improves clinical variables after 2h: respiratory rate decreased from 33 ± 6 breaths/min to 23 ± 3 breaths/min; PaO 2 increased from 48.7 (38 - 59)mmHg to 81.1 (76 - 90) mmHg; PaO 2 /FiO 2 ratio increased from 102.4 ± 32.2 to 136.6 ± 29.4; SatO 2 increased from 85 (66 - 92)% to 96 ± (95 - 97)%. HFNC could be an effective alternative in the treatment of acute respiratory failure from acute exacerbations of fibrotic ILD. |
Databáze: | OpenAIRE |
Externí odkaz: |